Home > conferences > conferences listings > conference details
Bookmark and Share email this event to a colleage
02 September 2010
life sciences/pharma sector

2nd Annual Antibody Discovery and Development Forum
Addressing and Overcoming the Key Challenges in Preclinical and Clinical Development

Event Date: 14-15 May 2009
Location: Palace Hotel, Berlin, Germany

key conference speakers

Dr. Josi Holz
Chief Medical Officer, Ablynx NV
Dr. Yiqing Feng
Assistant Director, Protein Engineering, Centocor Inc
Prof. Jan van de Winkel
Chief Scientific Officer, Genmab BV
Dr. Chengbin Wu
Associate Research Fellow, Volwiler Society, Abbott Labs
Dr. Michael Stumpp
Chief Scientific Officer, Molecular Partners AG

key conference topics

  • Understand how to shorten timelines
  • Investigate the impact of discovery on manufacturability, expression and formulation
    •
  • Learn how affinity and potency affect downstream pharmacology
  • Identify what companies need to think about when choosing new projects
    •
  • Gain insight into next-generation therapeutics
    •

    key conference features

  • Key developments in discovery
  • Linking discovery to the clinic
    •
  • Clinical case studies
    •
  • What's next for the antibody field?
    •
    conference focus

    Widely hailed by analysts as the medicine of the future, the efficacy of body lang=EN-US style='tab-interval:36.0pt'>

    Widely hailed by analysts as the medicine of the future, the efficacy of

    antibody therapeutics has improved greatly in recent years, largely as a

    result of innovation in antibody technology. As upstream development

    improves across the board and companies’ technological capabilities

    reach a level playing field, the real advances in the clinic will be made

    by those who can apply this technology most effectively. This marcus

    evans forum will provide ample opportunity to network with peers

    and key opinion leaders in the antibody field and discuss winning

    strategies to successfully harness this technological know-how and

    drive progress.

    >

    conference sponsors
    Sponsor


    ProGenosis

    		 Media Partner


    Anti-Infective Drug News

    Media Partner


    Autoimmune Drug Focus

    who should attend the conference

    Vice Presidents, Heads, Directors, Area Leaders and Project Leaders Worldwide of:

    • Antibody Discovery
    • Antibody Technology/ Engineering/ Expression
    • Biotechnology/ Biologics
    • Protein Engineering/ Protein Technology
    • Preclinical/ Clinical R&D
    • Immunology
    • Medical Directors
    • Therapeutic Areas (specific to disorder)

    From Market-Leading Pharmaceutical, Biopharmaceutical and Biotechnology Companies

    the conference organisers

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.

    sector information
    sector listings


    conference speakers

    Dr. Josi Holz
    Chief Medical Officer
    Ablynx NV

    Dr. Philippe Stas
    Chief Executive Officer
    AlgoNomics NV

    Dr. William Strohl
    Executive Director, Department of Biologics Research
    Centocor Inc

    Dr. Yiqing Feng
    Assistant Director, Protein Engineering
    Centocor Inc

    Dr. Ben Woolven
    Manager, Biopharm CEDD
    Domantis Ltd

    Prof. Jan van de Winkel
    Chief Scientific Officer
    Genmab BV

    Dr. Wim Bleeker
    Director, Translational Res and Pharmacology
    Genmab BV

    Dr. Fabrizio Giannotta
    Chief Executive Officer
    ProGenosis SA

    Prof. Dr. Thomas Valerius
    Section for Stem Cell Transplantation and Immunotherapy
    Christian-Albrechts-University, Kiel

    Prof. Dr. Arne Skerra
    Chair of Biological Chemistry
    Technical University of Munich

    Dr. Chengbin Wu
    Associate Research Fellow, Volwiler Society
    Abbott Labs

    Dr. Peter Lichtlen
    Head of Clinical Research and Development
    ESBATech AG

    Dr. Tobias Raum
    Senior Director, Lead Discovery
    Micromet AG

    Dr. Michael Stumpp
    Chief Scientific Officer
    Molecular Partners AG

    Dr. Cornelis L. Verweij
    Professor of Molecular Biology and Biochemistry and Head of Inflammatory Disease Profiling
    VU University Medical Center

    general enquiries

    Ola Samuelsson

    11 Connaught Place
    London
    W2 2ET

    Telephone:     +44(0)20 3002 3276
    Fax: +44(0)20 3002 3016
    Email: olas@marcusevansuk.com


    sponsorship opportunities

    Nisha Vyas

    11 Connaught Place
    LONDON
    W2 2ET

    Telephone: +44(0)20 3002 3171
    Fax: +44 (0)20 3002 3484
    Email: nishav@marcusevansuk.com

    conference quote

    "Effectively harnessing technological know-how in discovery to enhance clinical efficacy"

    With the majority of companies now having similar capabilities in antibody production, there is keen interest in evaluating the knock-on effects downstream and assessing clinical feedback and results. Hear how technological innovation in early discovery has impacted later-stage development and how this technology can be exploited most effectively to progress the next generation of antibody therapeutics.